Analysis of the main functions, indications and mechanism of action of Leborexan (Davico) tablets

Lemborexant (trade name: Dayvigo) is a new type of oral sleep regulating drug that belongs to the dual oxygen receptor antagonist (DORA, Dual Orexin Receptor Antagonist) class of drugs. Its main function is to inhibit wakefulness maintenance signals by selectively antagonizing Orexin 1 (OX1R) and Orexin 2 (OX2R) receptors in the brain, thereby promoting sleep. Unlike traditional benzodiazepines, leborexan does not induce sedation by directly enhancing the activity of γ-aminobutyric acid (GABA), but achieves sleep initiation by regulating wakeful neural pathways. Therefore, it has the characteristics of stable sedative effect, relatively low side effects, and little impact on cognition and memory.

The main effect of Lebraxen is to improve the difficulty in falling asleep and maintaining sleep in patients with insomnia. Clinical trials have shown that for patients who have difficulty falling asleep, leborexan can significantly shorten the sleep onset latency (Sleep Onset Latency, SOL), and most patients can fall asleep within one hour after taking the drug. At the same time, for patients who are prone to waking up at night or who suffer from sleep disorders, Lebraxen can extend the total sleep time (Total Sleep Time, TST), reduce the number of nighttime awakenings, and thus improve the overall sleep quality. In addition, compared with benzodiazepines, their effects are more sustained and the risk of dependence and tolerance is lower.

In terms of indications, Leborexan is mainly used for the treatment of insomnia in adults. According to FDA and EMA approval, leborexan is suitable for adult patients with long-term or short-term difficulty falling asleep and maintaining sleep. Especially for middle-aged and elderly people, its drug safety and tolerability advantages are obvious. In clinical practice, leborexan is often used as a non-benzodiazepine alternative in patients with insomnia, especially those with cognitive function concerns or those at risk for drug dependence. When taking it, it is usually recommended to take the medicine 30 minutes to 1 hour before going to bed, and ensure at least 7 hours of sleep to achieve the best effect.

The mechanism of action of Leborexin is mainly through inhibiting theOrexin nervous system. Orexin (also known as Hypocretin) is a neuropeptide secreted by the hypothalamus, which maintains the awake state mainly through OX1R and OX2R receptors. Patients with insomnia are often accompanied by an overactive Orexin system, which causes the wake-up signal to continue to function and makes it difficult to fall asleep or maintain sleep. Leborexan reduces wakefulness signaling by selectively blocking OX1R and OX2R receptors, thereby reducing wakefulness and promoting natural sleep. Compared with GABA receptor agonists, this mechanism does not directly inhibit neural activity, so it has less impact on cognition, memory and muscle tone, reducing daytime sleepiness and the risk of falls.

In terms of pharmacokinetics, leborexan is rapidly absorbed after oral administration and has high bioavailability. The peak concentration is generally reached 1 to 3 hours after taking the drug. Its half-life is approximately 17 to 19 hours, allowing the drug to continue to work at night while blood levels are relatively low during the day, thereby reducing the risk of daytime drowsiness or decreased concentration. The drug is primarily excreted via hepatic metabolism (CYP3A4), so dose adjustment is required in patients receiving concomitant CYP3A4 inhibitors or inducers.

In addition, leborexan has shown good safety and tolerability in clinical studies. Common adverse reactions include mild daytime drowsiness, headache, fatigue or dry mouth, which are mostly mild to moderate and controllable. No significant drug dependence or tolerance problems have been found in long-term use, so it is suitable for long-term use by patients with chronic insomnia. For patients with hepatic insufficiency or elderly patients, doctors will adjust the starting dose according to the specific situation to ensure safety.

In general, Lemborexant (Lemborexant) regulates the balance between wakefulness and sleep by antagonizing Orexin receptors, which can significantly improve the difficulty in falling asleep and night awakening, extend the total sleep time, and improve sleep quality. It’s notGABAmechanism, low dependence, and minor cognitive side effects, giving it unique advantages in the treatment of adult insomnia. In clinical use, Lebraxen can provide a safe, effective and sustainable sleep improvement solution for insomnia patients through reasonable dosage and sleep time management.

Reference link:https://www.drugs.com